There is no agreement on the standard chemotherapeutic regimen for biliary tract cancer (BTC), although multi-drug regimens such as gemcitabine and/or S-1 have been tested in clinical trials. This study retrospectively reviewed data from patients with BTC who were seen at hospitals in the Kitakyushu and Fukuoka areas between 2005 and 2006, and examined the effect of systemic chemotherapy regimen on survival benefits in patients with unresectable BTC. Chemotherapy may benefit patients with BTC any age group, regardless of the primary site.
|ジャーナル||Japanese Journal of Cancer and Chemotherapy|
|出版ステータス||出版済み - 12 2010|
All Science Journal Classification (ASJC) codes